Chemistry:Esaxerenone
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Minnebro |
| Other names | CS-3150; XL-550 |
| Routes of administration | By mouth |
| Drug class | Antimineralocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H21F3N2O4S |
| Molar mass | 466.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Esaxerenone (INN) (brand name Minnebro; developmental code names CS-3150, XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the treatment of hypertension.[1][2][3] It acts as a highly selective silent antagonist of the mineralocorticoid receptor (MR), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the MR relative to the existing antimineralocorticoids spironolactone and eplerenone.[1][2][3] As of January 2019, esaxerenone is in phase III clinical trials for diabetic nephropathies.[1]
See also
References
- ↑ 1.0 1.1 1.2 "Esaxerenone - Daiichi Sankyo - AdisInsight". http://adisinsight.springer.com/drugs/800021527.
- ↑ 2.0 2.1 "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Curr Opin Pharmacol 27: 78–85. 2016. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
- ↑ 3.0 3.1 "Nonsteroidal antagonists of the mineralocorticoid receptor". Curr. Opin. Nephrol. Hypertens. 24 (5): 417–24. 2015. doi:10.1097/MNH.0000000000000147. PMID 26083526.
External links
 |  |
